Nuwellis, Inc. quarterly report, Q1 FY2016

Business context and reporting period

Sunshine Heart, Inc. (the registrant named in this filing) filed this Form 10-Q for the quarter ended March 31, 2016. It was developing the C-Pulse System, an investigational heart-failure device. In March 2016, the company stopped enrolling patients in its COUNTER HF and OPTIONS HF studies and said it was developing a revised clinical and product strategy.

Key financial metrics

Gross margin is not meaningful given no Q1 2016 sales; the filing does not provide a clear margin measure. Cash declined by $6.643 million in the quarter. Investing cash outflow was $8,000; financing cash outflow was $940,000, primarily debt principal repayments. Interest expense was $229,000, up from $63,000.

Material changes versus the prior comparable period

• Revenue fell from $59,000 to zero; the company did not expect C-Pulse System sales revenue in fiscal 2016 after ending enrollment in the clinical trials.
• SG&A decreased 38.3% to $1.349 million, attributed to streamlining and lower stock compensation. R&D decreased 34.1% to $3.206 million, primarily following the trial enrollment decision.
• Net loss narrowed by $2.277 million, while operating cash use improved by $1.388 million. Q1 2015 included $6.9 million in net ATM equity proceeds and $6.0 million in debt proceeds; no similar financing was completed in Q1 2016.
• Cash fell from $23.113 million at year-end 2015 to $16.470 million at quarter-end.

Outlook, risks and contingencies

• Management expected R&D costs to decrease during 2016 after trial enrollment stopped, but said costs could rise later as it funds development of a fully implantable system and implements a new clinical strategy. No quantified earnings or revenue guidance was provided.
• The company expected to seek additional financing during 2016 and cautioned that failure to raise capital could threaten its ability to continue as a going concern. It had an accumulated deficit of $158.0 million and expected losses to continue.
• The SVB loan carried a 7% annual interest rate and required monthly principal repayments beginning January 2016. Its liquidity covenant required cash and equivalents of at least eight times monthly cash utilization; the company reported compliance at March 31, 2016. The facility is secured by company assets, subject to stated exceptions.
• NASDAQ notified the company that its share price had been below $1 for 30 consecutive business days. It had until September 19, 2016 to regain compliance; otherwise, a reverse split or delisting could result. The filing warned delisting could impair fundraising.
• The C-Pulse System was not approved for commercial sale in the U.S.; regulatory approval, clinical strategy execution, commercialization, and access to capital remained key uncertainties. The company reported no material legal proceedings and no material capital expenditure commitments.

Important facts for investors to verify

• Progress, timing, funding needs, and regulatory implications of the revised product and clinical strategy after trial enrollment ended.
• Cash runway and ability to raise additional capital, including the effect of debt service and the SVB liquidity covenant.
• NASDAQ listing compliance status and any reverse split or delisting developments.
• Commercialization prospects and regulatory status of the C-Pulse System; the filing provides no assured timeline or approval outcome.
• The filing identifies the registrant as Sunshine Heart, Inc.; verify the issuer identity against the intended company and filing.